Magazine Article | December 29, 2016

Why Pet Health Is The Focus Of A New Biotech Sector

Source: Life Science Leader

By Cathy Yarbrough, Contributing Editor
Follow Me On Twitter @sciencematter

For Aratana Therapeutics, 2016 was a banner year. The biotech company, founded in 2010, achieved FDA approvals for three of its 10 pipeline drugs. Last year the Kansas City-based company also forged a global partnership with the pharmaceutical giant Eli Lilly, a track record that any young biotech company would like to achieve.

But Aratana is not a typical biotech company. It is one of several companies launched during the past decade to develop cutting-edge small molecule and biologic drugs for dogs and cats with cancer, osteoarthritis, and the other chronic disorders that afflict pets as they age. These new companies are part of a $24 billion animal health industry, which is dominated by Zoetis and several other large multinational companies that produce vaccines, parasiticides, and other products for livestock as well as companion animals. But a very small part of these companies’ business is focused on the medical needs of pets with serious diseases.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: